GLP-1 Agonists: Beyond Weight Loss, Into Inflammation

by Dr. François Dufresne
Private Medical New York, Internal Medicine

Glucagon-like peptide-1 (GLP-1) receptor agonists have fundamentally transformed the treatment landscape for type 2 diabetes and obesity over the past decade.

Originally developed to improve glycemic control, these compunds—including semaglutide, liraglutide, and tirzepatide—have demonstrated remarkable efficacy in promoting weight loss, with reductions ranging from 7-24% of body weight in clinical trials.

Beyond these well-established metabolic benefits, mounting evidence suggests that GLP-1 receptor agonists may exert powerful anti-inflammatory effects that extend well beyond what might be expected from weight loss alone.

Chronic low-grade inflammation represents a common pathological thread linking many of the conditions most relevant to longevity and healthspan:  cardiovascular disease, metabolic dysfunction, neurodegenerative disorders, and even certain cancers such as colorectal cancer. The recognition that GLP-1 receptor agonists might address this fundamental driver of disease has sparked considerable scientific interest and investigation.

Clinical data

Clinical trial data provides compelling evidence for weight loss-independent anti-inflammatory effects. In the semaglutide SUSTAIN and PIONEER trials, reductions in glucose and weight explained only 20-60% of the observed decreases in C-reactive protein (CRP), a key marker of systemic inflammation. Particularly striking was the PIONEER 2 trial, where oral semaglutide reduced CRP by 30%, while empagliflozin—despite producing similar weight loss of approximately 4%—had no effect on inflammatory markers. These findings suggest that GLP-1 receptor agonists operate through mechanisms that are at least partially independent of their metabolic effects.

MOA

The proposed mechanisms underlying these anti-inflammatory properties are multifaceted. GLP-1 receptor agonists appear to inhibit nuclear factor kappa B (NF-κB) signaling, a critical pathway in inflammatory responses. They reduce production of pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β). Additionally, these medications modulate immune cell activity, influencing macrophage polarization and microglial activation. Proteomic analyses from the STEP weight loss trials revealed semaglutide-induced changes in inflammatory and immune regulatory pathways that could not be fully attributed to metabolic improvements alone, further supporting the existence of direct anti-inflammatory mechanisms.

The clinical implications of these anti-inflammatory properties extend across multiple organ systems. In cardiovascular disease, GLP-1 receptor agonists have demonstrated 14-20% reductions in major adverse cardiovascular events. In metabolic dysfunction-associated steatotic liver disease (MASLD), they reduce hepatic steatosis and fibrosis by modulating inflammation in hepatocytes and Kupffer cells. Studies have also shown nephroprotective effects through reduction of renal inflammation and oxidative stress, even in non-diabetic models.

ALZ Fail

However, recent clinical trial results provide an important reminder about the limits of single therapeutic interventions, even for medications with such broad-ranging benefits. In November 2024, Novo Nordisk announced that their phase 3 EVOKE and EVOKE+ trials—which enrolled nearly 4,000 patients with early-stage Alzheimer’s disease—failed to demonstrate that oral semaglutide could slow cognitive decline compared to placebo. Despite improvements in Alzheimer’s-related biomarkers, including reductions in neuroinflammatory markers, the drug did not measurably reduce cognitive and functional decline compared to placebo over two years.

This setback highlights a critical principle in medicine: even medications with proven anti-inflammatory effects may not universally slow disease progression across all conditions. The failure likely reflects the complexity of neurodegenerative diseases, which involve multiple overlapping pathological processes beyond inflammation alone. As researchers noted, GLP-1 agonists may still hold promise for prevention of Alzheimer’s disease, given that observational data suggests reduced dementia incidence in long-term users.

Future

Looking forward, the expanding recognition of GLP-1 receptor agonists as anti-inflammatory agents opens exciting possibilities. Ongoing investigations are exploring their potential in inflammatory bowel disease, psoriasis, rheumatoid arthritis, and other inflammatory conditions. The key will be understanding which populations and disease stages might benefit most from these pleiotropic effects.

For those of us interested in preventative health and avoidance of chronic disease, GLP-1 receptor agonists represent a powerful tool—but not an elixir. Their anti-inflammatory properties, combined with metabolic benefits, position them as potentially valuable interventions for reducing the chronic low-grade inflammation that accelerates aging and drives disease. Yet the Alzheimer’s trial results remind us that even promising therapies have boundaries.

The journey of GLP-1 receptor agonists continues to evolve, and their story is far from over.